Article citationsMore>>

Frenette, A.J., Kanji, S., Rees, L., Williamson, D.R., Perreault, M.M., Turgeon, A.F., et al. (2012) Efficacy and Safety of Dopamine Agonists in Traumatic Brain Injury: A Systematic Review of Randomized Controlled Trials. Journal of Neurotrauma, 29, 1-18.
https://doi.org/10.1089/neu.2011.1812

has been cited by the following article:

• TITLE: Bromocriptine in Central Hyperthermia after Severe Traumatic Brain Injury

  AUTHORS: Tamer Zakhary, Ahmed Sabry

  KEYWORDS: Critical, Neurology, Traumatic Brain Injury, Central Hyperthermia, Bromocriptine

  JOURNAL NAME: Open Journal of Emergency Medicine, Vol.5 No.3, September 15, 2017

  ABSTRACT: Strong evidence showed that fever after traumatic brain injury TBI is associated with increased mortality. In this study, we tried to evaluate the role of Bromocriptine in central hyperthermia in patients with severe TBI. This prospective controlled study was conducted on 50 severe TBI patients who admitted to the critical care department and confirmed on Computed Tomography (CT) of the brain and GCS of less than 9 at admission. Then, they were randomly assigned into 2 groups. Bromocriptine group (25) received bromocriptine 7.5 mg/day during 24 hours from admission through a naso-gastric (NG) feeding tube. Control group (25) received conventional treatment only. Temperature was measured every 2 hours. The antipyretic measures used were the same across all patients enrolled. The primary outcome was number of patients diagnosed with central hyperthermia. After the discharge of all patients, there was a statistically significant difference between the 2 groups in number of patients diagnosed with central hyperthermia (6 (24%) in bromocriptine group Vs 18 (72%) in control, p = 0.002). There were no differences in hospital length of stay (p = 0.904) or mortality (p = 0.393). Early administration of bromocriptine in severe TBI may be associated with lower incidence of central hyperthermia with no effect on length of stay or mortality.